![](/img/cover-not-exists.png)
A multicentre, randomised, double-blind, placebo controlled, parallel group study to investigate the efficacy and tolerability of leucomax® (molgramostim; rHu GM-CSF) in conjunction with combination chemotherapy in the treatment of intermediate / poor prognosis patients with small cell lung cancer (SCLC)
Volume:
11
Language:
english
Journal:
Lung Cancer
DOI:
10.1016/0169-5002(94)94149-1
Date:
June, 1994
File:
PDF, 143 KB
english, 1994